WO2022211798A1 - Personalized skin care compositions - Google Patents
Personalized skin care compositions Download PDFInfo
- Publication number
- WO2022211798A1 WO2022211798A1 PCT/US2021/025058 US2021025058W WO2022211798A1 WO 2022211798 A1 WO2022211798 A1 WO 2022211798A1 US 2021025058 W US2021025058 W US 2021025058W WO 2022211798 A1 WO2022211798 A1 WO 2022211798A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- sample
- milk
- personalized
- care composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/882—Mixing prior to application
Definitions
- This disclosure is directed to personalized skin care compositions, kits and methods for making personalized skin care compositions, and methods of treating or preventing skin conditions using personalized skin care compositions.
- Diaper rash has been attributed to a number of different factors in the diapered environment such as stratum comeum over hydration, friction damage, reduced natural moisturization factor (NMF), and exposure to irritants contained in urine, feces, and extrinsic chemicals.
- the diapered skin is comprised of a very diverse microbiota made up of endemic and transient (GI tract) microbes.
- GI tract endemic and transient
- a personalized skin care composition using paired mother-infant microbiome samples can be used to mitigate or eliminate diaper rash. These methods maintain a personalized healthy diapered skin microbiome specific to each infant, rather than using a generalized approach as is seen when routinely administering oral probiotics. There is an unmet need for personalized skin care compositions for diaper rash and other skin conditions.
- the aim of the present disclosure is to provide personalized skin care compositions and kits and methods for making personalized skin care compositions.
- the personalized skin care compositions are useful for treating or preventing skin conditions.
- a personalized skin care composition comprising a cultured composition comprising a milk sample acquired from breast milk or baby formula and a skin sample acquired from a healthy skin area of a subject, and optionally an additive.
- kits for making a personalized skin care composition comprising a sterile implement, a sterile collection vial, a sterile, hydrophobic container comprising etching for biofilm formation, a lid, and a filter allowing for gas exchange, optionally a breast pump, and written instructions for making the personalized skin care composition, comprising the method steps of (i) acquiring a milk sample from breast milk or baby formula using the sterile collection vial and optionally the breast pump, (ii) acquiring a skin sample from a healthy skin area of a subject using the sterile implement, (iii) transferring the milk sample to the sterile, hydrophobic container and mixing the milk sample and the skin sample, and (iv) culturing the milk sample and the skin sample to yield the personalized skin care composition.
- a method of making a personalized skin care composition comprising (i) acquiring a milk sample from breast milk or baby formula, (ii) acquiring a skin sample from a healthy skin area of a subject, (iii) mixing the milk sample and the skin sample, and (iv) culturing the milk sample and the skin sample to yield the personalized skin care composition.
- a method of treating or preventing a skin condition in a skin area in need thereof comprising (i) acquiring a milk sample from breast milk or baby formula, (ii) acquiring a skin sample from a healthy skin area of a subject, (iii) mixing the milk sample with the skin sample, (iv) culturing the milk sample and skin sample to yield a personalized skin care composition, and (v) applying an effective amount of the personalized skin care composition to the skin area in need thereof of the subject.
- Figure 1 is an exemplary embodiment of a kit containing a sterile, hydrophobic container, a sterile collection vial, and a sterile implement in accordance with the present disclosure.
- the present disclosure generally relates to personalized skin care compositions comprising a cultured milk sample and skin sample, and optionally an additive.
- the present disclosure relates to personalized skin care compositions comprising a cultured milk sample from the breast milk of a human mother and a skin sample from a breastfed child of the mother.
- kits and methods for making the personalized skin care compositions, as well as methods of treating or preventing skin conditions using the personalized skin care compositions are particularly useful for treating or preventing diaper rash.
- the personalized skin care compositions in accordance with the present disclosure comprise a cultured composition comprising a milk sample and a skin sample, and optionally an additive.
- the milk sample is acquired from breast milk or baby formula.
- the skin sample is acquired from a healthy skin area of a subject.
- the personalized skin care compositions in accordance with the present disclosure may be prepared by any of the methods discussed herein.
- the personalized skin care composition may be prepared according to a method comprising (i) acquiring the milk sample from breast milk or baby formula, (ii) acquiring the skin sample from a healthy skin area of a subject, (iii) mixing the milk sample and the skin sample, and (iv) culturing the milk sample and the skin sample to yield the personalized skin care composition.
- the method of making a personalized skin care composition further comprises adding an additive.
- the additive may be added at any step of the method.
- the additive is added after culturing the milk sample and the skin sample to yield the personalized skin care composition.
- the personalized skin care composition comprises a cultured composition comprising a milk sample acquired from breast milk of a human mother, and a skin sample acquired from a healthy skin area of the mother’s child.
- the child is a breastfed child and/or the child’s diet is comprised primarily of the mother’s breast milk.
- the child is a human infant.
- the milk sample in accordance with the present disclosure may be any milk sample known in the art.
- the milk sample may be a natural milk sample acquired from a natural source or a synthetic milk sample acquired from a synthetic source. Natural milk samples may be expressed from a subject. Synthetic milk samples may be acquired from synthetic breast milk or baby formula.
- the milk sample is acquired from a natural source, such as the breast milk of a mammalian subject (e.g., a human mom).
- Acquiring the milk sample may comprise manually expressing the breast milk from the mammalian subject.
- Manual expression may include any means of manual expression known in the art, including manual expression by hand.
- Acquiring the milk sample may also, or alternatively, comprise expressing the breast milk using a breast pump, such as the sterile breast pump provided in the kits described herein.
- a breast pump such as the sterile breast pump provided in the kits described herein.
- the milk sample may be acquired from a synthetic source, such as baby formula.
- Baby formula as used herein refers to any synthetic or manufactured breast milk substitute designed for feeding babies or infants. Many different baby formulas are well known in the art and commercially available, any of which may be used in accordance with the present disclosure as desired.
- the baby formula comprises human milk oligosaccharides (HMOs).
- HMOs are polymers of simple sugars that are naturally occurring in human breast milk. HMOs may promote the colonization of intestinal microbes, such as the ones that are increased on the diapered skin of non-rash infants.
- HMOs include 2’-fucosyllactose, lacto- N-tetraose, 2’-sialyllactose, lacto-N-neotetraose, lacto-N-fucopentaose, and combinations thereof.
- the HMOs are selected from the group consisting of 2’-fucosyllactose, lacto-N-tetraose, and 2’-sialyllactose.
- the baby formula may also comprise prebiotics or probiotics.
- prebiotics refer to indigestible food ingredients that induce growth or activity of beneficial microorganisms, often in the gastrointestinal tract.
- Probiotics as used herein refer to living microorganisms or components of microorganisms that confer a beneficial effect on a subject when consumed.
- Prebiotics or probiotics administered through infant formula may be used to promote microbial health both in the gastrointestinal tract and on the skin.
- Non- limiting examples of probiotics include any species of Lactobacillus or Bifidobacterium.
- prebiotics include oligosaccharides, such as fructooligosaccharides or galactooligosaccharides, polydextrose, and combinations thereof.
- the milk sample may be acquired in any range of suitable amounts. Amounts are defined herein in milliliters (mL). In some embodiments, the milk sample is acquired in an amount from about 10 mL, about 20 mL, about 30 mL, about 40 mL, about 50 mL, about 60 mL, about 70 mL, about 80 mL, about 90 mL, about 100 mL, about 110 mL, about 120 mL, about 130 mL, about 140 mL, about 150 mL, about 160 mL, about 170 mL, about 180 mL, about 190 mL, about 200 mL, about 210 mL, about 220 mL, about 230 mL, about 240 mL, about 250 mL, about 260 mL, about 270 mL, about 280 mL, about 290 mL
- the skin sample in accordance with the present disclosure may be any skin sample known in the art.
- the skin sample in accordance with the present disclosure may be acquired by any known method of acquiring skin samples known in the art.
- the skin area from which the skin sample is acquired is a healthy skin area of a subject.
- a healthy skin area as used herein is any skin area that appears normal and does not exhibit, for example, significant brokenness, irritation, erythema, swelling, rash, or other signs of distress or disease.
- the healthy skin area should not include a skin area presently affected by a skin condition, examples of which are described herein. However, the healthy skin area may have been previously affected by a skin condition.
- the healthy skin area is a perianal skin area. In some preferred embodiments, the healthy skin area is a perianal skin area of a human infant. In some preferred embodiments, the healthy skin area is a buhock skin area of a human infant.
- the skin area in need thereof is a skin area presently experiencing a skin condition as described herein. In some embodiments, the skin area in need thereof is a skin area that has previously experienced a skin condition, but is presently healthy. In some embodiments, the skin area in need thereof is a skin area that is presently healthy and has not previously experienced a skin condition.
- the skin sample may be acquired by any method of acquiring a skin sample typically used in a clinical or laboratory setting or otherwise known in the art.
- the skin sample may be acquired by scraping a sterile implement against the healthy skin area.
- acquiring the skin sample may comprise gently rubbing or otherwise contacting a sterile implement against the healthy skin area of the subject.
- the acquired skin sample may be used immediately, or stored in a sterile container for future use, as desired.
- the skin sample provides microorganisms from the healthy skin area of the subject to the personalized skin composition. Because the skin sample is cultured, resulting in proliferation of the provided microorganisms, the skin sample need only provide an amount of microorganisms sufficient to proliferate to appreciable levels upon culturing. Therefore, the skin sample may be acquired in any range of suitable amounts. Generally, bacteria are discussed in log numbers.
- the skin sample is acquired in an amount of from about 0-10 CFU/mL, about 11-100 CFU/mL, about 101-1000 CFU/mL, about 1001 - 10000 CFU/mL, about 10,001-100,000 CFU/mL, or about 100,001-1,000,000 CFU/mL to about 11-100 CFU/mL, about 101-1000 CFU/mL, about 1001-10000 CFU/mL, about 10,001-100,000 CFU/mL, or about 100,001-1,000,000 CFU/mL.
- the skin sample is acquired in an amount of about 0-10 CFU/mL, about 11-100 CFU/mL, about 101-1000 CFU/mL, about 1001-10000 CFU/mL, about 10,001-100,000 CFU/mL, or about 100,001-1,000,000 CFU/mL.
- the skin sample is acquired from the subject after the subject has ingested breast milk or baby formula from the source from which the milk sample is acquired.
- the subject ingests a first amount of breast milk or baby formula from a source of the breast milk or baby formula, and then a second amount of the breast milk or baby formula from the source of the breast milk or baby formula is mixed with a skin sample that is acquired from the subject after the subject has ingested the first amount of the breast milk or baby formula, and the mixture is cultured to yield the personalized skin care composition.
- a regular diet of the subject comprises the breast milk or baby formula from which the milk sample is acquired.
- the skin sample is acquired from a human child or infant that regularly consumes breast milk from which the milk sample is acquired.
- the intestinal microbiome which may transiently colonize the skin, as well as the endemic skin microbiome, are affected by diet. Therefore, the personalized skin care composition of the present disclosure is expected to at least in part mimic the healthy skin microbiome of the subject.
- the ratio of milk sample to skin sample in the personalized skin care composition of the present disclosure there are no limitations as to the ratio of milk sample to skin sample in the personalized skin care composition of the present disclosure.
- the amount of the milk sample is greater than the amount of the skin sample in the personalized skin care composition.
- a ratio of milk sample to skin sample may be used such that the volume of the milk sample is sufficient to submerge the skin sample and/or a sterile implement used to acquire the skin sample.
- the milk sample and skin sample are present in the personalized skin care composition in a ratio in the range of from about 1000:1 to 1:1000 by wt%. In some embodiments, the milk sample and skin sample are present in the personalized skin care composition in a ratio in the range of from about 100:1 to 1:100 by wt%. In some embodiments, the milk sample and skin sample are present in the personalized skin care composition in a ratio in the range of from about 10:1 to 1:10 by wt%.
- the subject is an animal subject, a human subject, or a non-human animal subject.
- the subject may be any age or gender. Non limiting examples include male infants, female infants, male toddlers, female toddlers, male children, female children, male adults, female adults, elderly males, and elderly females.
- the subject is a human subject.
- the subject is a human child. In some preferred embodiments, the subject is a human infant.
- the cultured composition comprised in the personalized skin care composition may be obtained by any of the culturing methods as discussed herein.
- the culturing in accordance with the present disclosure may be any culturing method known in the art.
- Culturing as used herein generally refers to maintaining the cultured composition comprising the milk and skin sample under any conditions that allow for the growth of microorganisms.
- the cultured composition comprising the milk and skin sample may be cultured at any range of suitable temperatures. Temperatures are defined herein in degrees Celsius (°C).
- the cultured composition comprising the milk sample and skin sample is cultured at a temperature of from about 0 °C, about 1 °C, about 2 °C, about 3 °C, about 4 °C, about 5 °C, about 6 °C, about 7 °C, about 8 °C, about 9 °C, about 10 °C, about 11 °C, about 12 °C, about 13 °C, about 14 °C, about 15 °C, about 16 °C, about 17 °C, about 18 °C, about 19 °C, about 20 °C, about 21 °C, about 22 °C, about 23 °C, about 24 °C, about 25 °C, about 26 °C, about 27 °C, about 28 °C, about 29 °C, about 30 °C, about 31 °C, about 32 °C, about 33 °C, about 34 °C, about 35 °C, about 36 °C, about 37
- the cultured composition comprising the milk sample and skin sample is cultured at a temperature of from about 15 °C to about 30 °C.
- the cultured composition comprising the milk sample and skin sample may be cultured for any range of suitable durations.
- the cultured composition comprising the milk and skin sample are cultured for a duration of about 24 hours, about 48 hours, about 72 hours, about 96 hours, about 120 hours, about 144 hours, about 168 hours, about 192 hours, about 216 hours, about 240 hours, about 264 hours, about 288 hours, about 312 hours, about 336 hours, about 360 hours, about 384 hours, about 408 hours, about 432 hours, about 456 hours, about 480 hours, or about 504 hours, to about 24 hours, about 48 hours, about 72 hours, about 96 hours, about 120 hours, about 144 hours, about 168 hours, about 192 hours, about 216 hours, about 240 hours, about 264 hours, about 288 hours, about 312 hours, about 336 hours, about 360 hours, about 384 hours, about 408 hours, about 432 hours, about 456 hours, about 480 hours, about 504 hours, or
- the cultured composition comprising the milk and skin sample is cultured for a duration of from about 1 week, about 2 weeks, about 3 weeks, or more than about 4 weeks, to about 1 week, about 2 weeks, about 3 weeks, or more than about 4 weeks. In some preferred embodiments, the cultured composition comprising the milk and skin sample is cultured for a duration of from about 1 week to about 2 weeks.
- Culturing the milk sample and the skin sample may allow beneficial microorganisms present in the milk sample or the skin sample to proliferate. Therefore, culturing the milk sample and the skin sample may result in beneficial microorganisms being present in the personalized skin care composition.
- culturing a milk sample from breast milk of a human mother and a skin sample from a breastfed child of the mother provides a personalized skin composition comprising beneficial microorganisms endemic to the mother’s breast milk, the child’s skin, and/or the child’s gastrointestinal tract.
- culturing the milk sample and the skin sample may provide any beneficial microorganism, such as those belonging to the genera including Bacterioides, Balutia, Bifidobacterium, Brevundimonas, Burkholderia, Chryseobacterium, Clostridium, Corynebacterium, Enhydrobacter, Enterobacter, Enterococcus, Escherichia, Faecalibacterium, Flavobacterium, Lactobacillus, Leuconostoc, Micrococcus, Parabacteroides, Prevotella, Propionibacterium, Propionibacterium, Ralstonia, Rothia, Serratia, Sphingomonas, Staphylococcus, Stenotrophomonas , Streptococcus, Variovorax, Weissella, and combinations thereof.
- beneficial microorganism such as those belonging to the genera including Bacterioides, Balutia, Bifidobacterium, Brevundimonas, Burkholderia,
- Non-limiting examples of specific beneficial microorganisms that may be provided in the personalized skin care composition include Faecalibacterium prausnitzii, Bacteroides caccai, Bacteroides fragilis, Bacteroides stercoris, Bacteroides xylanisolvens, Parabacteroides distansonis, Prevotella copri, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium bifldum, Bifidobacterium adolescentis, Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus paracasei, and combinations thereof. These microorganisms are associated with healthy skin and the post-diaper rash recovered state.
- culturing the milk sample and the skin sample forms a biofilm in addition to a liquid component, both of which comprise the resulting personalized skin care composition.
- a biofilm is a solid film or gel-like substance that generally comprises multiple communal species of microorganisms.
- the biofilm is a symbiotic culture of bacteria and yeast, commonly known as a “SCOB” or “SCOBY”.
- the bacteria can be, for example, lactic acid bacteria or acetic acid bacteria, such as Bifidobacterium and Lactobacillus. The bacteria may also be present in the liquid component.
- the personalized skin care composition comprising the liquid component and/or biofilm is expected to provide beneficial properties upon application to the skin, due to the growth of lactic and acetic acid bacteria and the resulting lowering in skin pH.
- the lower pH provides antimicrobial properties which are effective against pathogens such as Group B Streptococcus and diaper rash-related organisms such as Staphylococcus aureus and Candida albicans.
- the personalized skin care compositions described herein may include additives.
- the additives as discussed herein may be added at any point before, after, or during culturing, as desired.
- the personalized skin care compositions described herein may include any additive conventionally found in cosmetic, pharmaceutical, medical, or personal care compositions/products in an established fashion and at established levels.
- the personalized skin care composition may comprise additional compatible pharmaceutically active and compatible materials for combination therapy, such as antioxidants, anti-parasitic agents, antipruritics, antifungals, biological actives, astringents, keratolytic actives, local anaesthetics, anti-stinging agents, anti -reddening agents, skin soothing agents, external analgesics, film formers, skin exfoliating agents, sunscreens, and combinations thereof.
- suitable additives include compatible colorants, deodorants, emulsifiers, anti-foaming agents (when foam is not desired), lubricants, skin conditioning agents, skin protectants and skin benefit agents (e.g., aloe vera and tocopheryl acetate), solvents, solubilizing agents, suspending agents, wetting agents, pH adjusting ingredients, chelators, propellants, dyes and/or pigments, and combinations thereof.
- fragrance Another component that may be suitable for addition to the personalized skin care composition is a fragrance. Any compatible fragrance may be used. Typically, the fragrance is present in an amount from about 0% (by weight of the composition) to about 5% (by weight of the composition), and more typically from about 0.01% (by weight of the composition) to about 3% (by weight of the composition). In one desirable embodiment, the fragrance will have a clean, fresh and/or neutral scent to create an appealing delivery vehicle for the end consumer.
- Organic sunscreens that may be present in the personalized skin care composition include ethylhexyl methoxycinnamate, avobenzone, octocrylene, benzophenone-4, phenylbenzimidazole sulfonic acid, homosalate, oxybenzone, benzophenone-3, ethylhexyl salicylate, and mixtures thereof.
- the personalized skin care compositions described herein may also or alternatively include any additive conventionally found in cultured compositions.
- additives that may be present in the personalized skin care composition include sugars, fatty acids, vitamins, minerals, serums, nucleotides, salts, buffers, water, agar, gelatin, dyes, enzymes, proteins, antifungals, and mixtures thereof.
- the personalized skin care compositions described herein do not comprise an additive.
- the personalized skin care compositions may not comprise an additive if, for example, it is desired that the personalized skin care compositions only include the endemic microbiomes of the milk sample and the skin sample.
- the personalized skin care compositions consist of a milk sample and a skin sample.
- the personalized skin care compositions consist of a breast milk sample acquired from a human mother and a skin sample acquired from a breastfed human child.
- kits for making the personalized skin care compositions described herein comprise a sterile implement, a sterile collection vial, a sterile hydrophobic container, and written instructions for making the personalized skin care composition.
- the sterile hydrophobic container comprises etching for biofilm formation, a lid, and a filter allowing for gas exchange.
- the written instructions comprise the method steps of acquiring a milk sample from breast milk or baby formula using the sterile collection vial, acquiring a skin sample from a healthy skin area of a subject using the sterile implement, transferring the milk sample to the sterile, hydrophobic container and mixing the milk sample and the skin sample, and culturing the milk sample and the skin sample to yield the personalized skin care composition.
- the written instructions for the kit for making a personalized skin care composition further comprises a method step of adding an additive.
- the additive may be added at any step of the instructions.
- the written instructions further comprise a method step of adding an additive after the method step of culturing the milk sample and the skin sample to yield the personalized skin care composition.
- the kit optionally comprises the additive.
- the kit may further comprise a breast pump.
- a breast pump as used herein refers to any mechanical device designed to pump or extract breast milk.
- the breast pump may comprise, for example, a pump, breast shields or flanges, valves, membranes, tubing, connectors, or backflow protectors.
- Many different breast pumps are well known in the art and commercially available, any of which may be used in accordance with the present disclosure as desired.
- the breast pump or its components discussed herein may be sanitized and/or sterilized by any method known in the art, non-limiting examples of which include boiling, microwaving, washing with soap and water, ultraviolet (UV) radiation, applying a chemical sanitizer, or steam cleaning.
- any method known in the art non-limiting examples of which include boiling, microwaving, washing with soap and water, ultraviolet (UV) radiation, applying a chemical sanitizer, or steam cleaning.
- UV radiation ultraviolet
- the milk sample is to be acquired by manually expressing breast milk, it may be desirable to sanitize and/or sterilize hands, typically by washing with soap and water and/or applying a chemical sanitizer, prior to acquiring the milk sample.
- the written instructions comprise a method step of acquiring a milk sample from breast milk using the breast pump and the sterile collection vial.
- kits described herein are suitable for use in the methods as discussed in the present disclosure.
- the kits may be used in the methods of making a personalized skin care composition in accordance with the present disclosure.
- the kits may be used in the methods of preventing or treating skin conditions in accordance with the present disclosure.
- Figure 1 is a schematic of an exemplary kit 100 for making the personalized skin care compositions in accordance with the present disclosure.
- the exemplary kit includes a sterile collection vial 130 comprising a lid 140 for acquiring the milk sample.
- the exemplary kit 100 also includes a sterile swab 110 provided in a sterile container 120 for acquiring the skin sample.
- a sterile, hydrophobic container 150 comprising a lid 160 and filter 170 is also provided in the exemplary kit 100
- a set of written instructions (not shown) detailing how to use the components of the exemplary kit 100 are also included.
- the kit components shown in Figure 1 are provided for illustrative purposes only and are not drawn to scale.
- a milk sample is acquired using the sterile collection vial provided in the kit in accordance with the present disclosure.
- Sterile generally refers to being free from bacteria or other living microorganisms.
- Sterile kit components as described herein limit introduction of contaminating microorganisms, e.g. microorganisms that are not naturally present in the milk sample or the skin sample, into the personalized skin care composition.
- the breast milk may be manually expressed directly into the sterile collection vial; alternatively, the sterile collection vial may be operatively connected to the breast pump such that the breast milk is directly extracted into the sterile collection vial.
- the baby formula may be prepared in or transferred into the sterile collection vial.
- the size or shape of the sterile collection vial there are no limitations as to the size or shape of the sterile collection vial. Any sterile collection vial that is suitable for holding or otherwise containing the milk sample acquired from breast milk or baby formula may be used.
- the sterile, collection vial may be a dish, a flask, a beaker, a bag, a bottle, ajar, a plate, a tube, or any other type of container known in the art.
- the sterile collection vial may comprise a lid configured to secure the contents of the sterile collection vial.
- the milk sample may be used immediately in the methods of the present disclosure or stored in the sterile collection vial for future use. It may be desirable to freeze the milk sample for long term storage, and thaw the milk sample for use in the methods of the present disclosure.
- acquiring a skin sample from a healthy skin area acquires microorganisms associated with healthy skin for use in the personalized skin care composition of the present disclosure.
- the skin sample is acquired using the sterile implement provided in the kits of the present disclosure.
- the sterile implement may be, for example, a sterile dry swab, a sterile sponge, a sterile loop, or a sterile tape strip.
- the sterile implement is a sterile dry swab.
- the sterile implement may be provided in a sterile container.
- the milk sample is transferred to a sterile, hydrophobic container provided in the kit in accordance with the present disclosure and mixed with the skin sample.
- Mixing the milk sample and skin sample in accordance with the present disclosure may include any means of combining or otherwise contacting the milk sample and skin sample.
- the milk sample may be stirred or touched by a portion of the sterile implement used to acquire the skin sample.
- the entire sterile implement used to acquire the skin sample may be placed into the milk sample.
- the combined milk sample and skin sample are cultured according to any of the culturing methods discussed herein in the provided sterile, hydrophobic container.
- the sterile, hydrophobic container may be a dish, a flask, a beaker, a bag, a box, a bottle, ajar, a plate, a tube, or any other type of container known in the art.
- the sterile, hydrophobic container may be comprised of any hydrophobic material known in the art to be suitable in the culturing methods as discussed herein.
- suitable hydrophobic materials include polystyrene, polyethylene terephthalate, low-density or high-density polyethylene, polyvinyl chloride, polypropylene, fluoropolymers, and combinations thereof.
- the provided sterile, hydrophobic container comprises etching, a lid, and a filter.
- Etching as used herein refers to an abraded or otherwise textured surface comprised in the sterile, hydrophobic container.
- the etching may be comprised on any and/or all surfaces of the sterile, hydrophobic container. It is well known that the texture of a surface influences adherence of microorganisms and the resulting formation of biofilms. Therefore, the etching comprised in the provided sterile, hydrophobic container is designed to encourage the formation of biofilms for use in the methods of the present disclosure.
- Etching may be achieved by any means known in the art to induce surface abrasion or texturing, including physical abrasion methods, such as grit-blasting or sand-blasting, or chemical abrasion methods, such as acid etching.
- the etching may be comprised in any pattern or otherwise regular, repeated design, or the etching may be comprised in a random configuration, as desired.
- the lid and filter comprised in the sterile, hydrophobic container there are no limitations as to the provided lid and filter comprised in the sterile, hydrophobic container, provided that the lid is configured to securely close the sterile, hydrophobic container and the filter is configured to allow for gas exchange between atmospheric air and the interior of the sterile, hydrophobic container.
- the filter may be configured to allow for the exchange of oxygen (O2), carbon dioxide (CO2), nitrogen (N2), water vapor, and mixtures thereof between atmospheric air and the interior of the sterile, hydrophobic container.
- the filter is configured to prevent entry of any component other than a gas into the interior of the sterile, hydrophobic container.
- the filter may be configured to prevent the entry of microorganisms, spores, dust, debris, particulates, or any other component of air that is not a gas into the interior of the sterile hydrophobic container.
- the filter is comprised in the lid.
- the filter may be comprised of any material known in the art to be suitable for use as a filter, including polypropylene, cellulose, cellulose esters, fiberglass, nylon, acrylic, polytetrafluoroethylene, polyvinylidene fluoride, polyethersulfone, and combinations thereof.
- the kit comprises any of the additives described herein for use in the personalized skin care composition.
- a first personalized skin care composition yielded by culturing the milk sample and the skin sample may be used to make at least one additional personalized skin care composition, as desired.
- kits described herein comprise at least one additional sterile, hydrophobic container for use in making additional personalized skin care compositions.
- a separate kit is provided comprising at least one additional sterile, hydrophobic container for use in making additional personalized skin care compositions.
- the first hydrophobic container used to make the first personalized skin care composition is cleaned and sterilized by any of the means discussed herein, and used to make the at least one additional personalized skin care composition.
- Making an additional personalized skin care composition may comprise transferring a portion of the first personalized skin care composition to the provided additional sterile, hydrophobic container.
- the portion of the first personalized skin care composition comprises a biofilm and a liquid component.
- An additional milk sample may then be acquired and transferred to the additional sterile, hydrophobic container.
- the additional sterile, hydrophobic container containing the portion of the first personalized skin care composition and the additional milk sample may then be cultured to yield an additional personalized skin care composition. This process may be repeated as desired in accordance with the kits and/or methods discussed herein.
- the methods of making a personalized skin care composition in accordance with the present disclosure generally comprise (i) acquiring a milk sample, (ii) acquiring a skin sample, (iii) mixing the milk sample and the skin sample, and (iv) culturing the milk sample and the skin sample to yield the personalized skin care composition.
- the milk sample, skin sample, and culturing thereof are as discussed herein in accordance with the present disclosure.
- the method of making a personalized skin care composition further comprises adding an additive.
- the additive may be added at any step of the method.
- the additive is added after culturing the milk sample and the skin sample to yield the personalized skin care composition.
- the methods of treating or preventing a skin condition in accordance with the present disclosure generally comprise (i) acquiring a milk sample, (ii) acquiring a skin sample, (iii) mixing the milk sample and the skin sample, (iv) culturing the milk sample and the skin sample to yield the personalized skin care composition, and (v) applying an effective amount of the personalized skin care composition to the skin area in need thereof of the subject.
- the milk sample, skin sample, and culturing thereof are as discussed herein in accordance with the present disclosure.
- the method of treating or preventing a skin condition in a skin area in need thereof further comprises adding an additive.
- the additive may be added at any step of the method.
- the additive is added after culturing the milk sample and the skin sample to yield the personalized skin care composition.
- Also provided are methods of using a personalized skin care composition The methods of using a personalized skin care composition in accordance with the present disclosure generally comprise using the personalized skin care composition to treat or prevent a skin condition.
- Also provided are uses of a personalized skin care composition The use of a personalized skin care composition in accordance with the present disclosure generally comprises using the personalized skin care composition to treat or prevent a skin condition.
- An effective amount of the personalized skin care composition as used herein generally refers to an amount of the personalized skin care composition that is sufficient to achieve a desired result.
- the desired result may be a reduction or mitigation of any of the symptoms or causes of the skin condition.
- the result may be a reduction in redness, swelling, irritation, discomfort, abnormal appearance, roughness, bumpiness, dryness, or scabness of the skin area to which the personalized skin care composition is applied.
- the desired result may be preventing or substantially delaying the appearance of any of the symptoms or causes of the skin condition described herein.
- applying an effective amount of the personalized skin care composition comprises topically applying a liquid component of the personalized skin care composition to the skin area in need thereof.
- the liquid component may be applied in any range of suitable amounts.
- the liquid component of the personalized skin care composition is applied in an amount of from about 0.10 mL, about 0.50 mL, about 1.0 mL, about 1.5 mL, about 2.0 mL, about 2.5 mL, about 3.0 mL, about 3.5 mL, about 4.0 mL, about 4.5 mL, about 5.0 mL, about 5.5 mL, about 6.0 mL, about 6.5 mL, about 7.0 mL, about 7.5 mL, about 8.0 mL, about 8.5 mL, about 9.0 mL, about 9.5 mL, or about 10.0 mL, to about 0.10 mL, about 0.50 mL, about 1.0 mL, about 1.5 mL, about 2.0 mL, about 2.5 mL, about 3.0 mL, about 3.5 mL, about 4.0 mL, about 4.5 mL, about 5.0 mL, about 5.5 mL, about 6.0
- the liquid component of the personalized skin composition may be applied to a skin area in need thereof by any suitable means known in the art. For example, it may be desired to apply the liquid component of the personalized skin care composition such that the skin area in need thereof is sufficiently covered by the liquid. In some embodiments, the liquid component may first be applied to a wipe which is then applied to the skin area in need thereof.
- applying an effective amount of the personalized skin care composition comprises topically applying a biofilm component of the personalized skin care composition to the skin area in need thereof.
- the biofilm component of the personalized skin composition may be applied to a skin area in need thereof by any suitable means known in the art. For example, it may be desired to apply the biofilm component of the personalized skin care composition such that the skin area in need thereof is sufficiently covered by the biofilm.
- Non-limiting examples of skin conditions in accordance with the present disclosure include diaper rash, rash, dermatitis, rosacea, eczema, psoriasis, hives, acne, cold sores, blisters, carbuncles, cellulitis, and combinations thereof.
- the skin condition is diaper rash. In some preferred embodiments, the skin condition is a skin condition known to be affected by diet.
- Example 1 Exemplary kit.
- An exemplary kit for making a personalized skin care composition may include the following components.
- [0097] 1 Sterile, 12 oz. hydrophobic container(s) comprising etching for biofilm formation and a lid with filter to allow for gas exchange
- [0098] 2 Tubed, sterile Dryswab (MWE medical wire, Corsham Wiltshire England, Tubed Sterile Dryswab, rayon, ref. MW102).
- Example 2 Breast milk sample collection.
- breast and hands Prior to collection, breast and hands should be cleaned with antibacterial soap and warm water. Electric breast pump, parts, and collection vial should be sanitized prior to collection. If breast milk is manually expressed, hands should also be properly sanitized.
- Example 3 Infant endemic/transient skin microbiome collection.
- the infant should be healthy and happy with no signs of fever, distress (such as teething), rash, vomiting, or diarrhea.
- the breast milk is expressed and transferred to a sterile, hydrophobic container.
- the swab is removed from the collection tube and placed in the transferred breast milk.
- the lid is returned to the sterile, hydrophobic container, with a filter to allow gas exchange but prevent contamination.
- the container is placed in a warm area and the culture is allowed to grow for 1 to 2 weeks. A liquid end product and a biofilm are formed.
- Example 5 Use of the personalized skin care composition to treat or prevent diaper rash.
- the liquid end product of the personalized skin care composition can be directly applied on infant’s diapered region as a rinse or applied using a wipe to prevent rash or during a rash episode.
- a layer of the biofilm can be peeled horizontally and used as a film in the baby’s diaper by covering the rashed area.
- the remaining layers can also be used or reserved for future batches.
- Example 6 Personalized skin care composition creation for future rash episodes.
- the culture is allowed to sit for 1 to 2 weeks in a warm place.
- compositions comprising, “comprising,” “includes,” “including,” “has,” “having,” “contains”, “containing,” “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated.
- a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method.
- transitional phrase “consisting essentially of’ is used to define a composition or method that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention.
- the term “consisting essentially of’ occupies a middle ground between “comprising” and “consisting of’.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2023010190A MX2023010190A (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions. |
| PCT/US2021/025058 WO2022211798A1 (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions |
| BR112023018682A BR112023018682A2 (en) | 2021-03-31 | 2021-03-31 | CUSTOM MAKEUP, KIT FOR MAKING A CUSTOM MAKEUP, METHOD FOR MAKING A CUSTOM MAKEUP, AND, USE OF THE CUSTOM MAKEUP |
| KR1020237036687A KR102746660B1 (en) | 2021-03-31 | 2021-03-31 | Customized Skin Care Composition |
| US18/547,601 US12508283B2 (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions |
| GB2315897.5A GB2619900B (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions |
| CN202180094818.2A CN116916888A (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions |
| AU2021437095A AU2021437095A1 (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions |
| US19/405,622 US20260083779A1 (en) | 2021-03-31 | 2025-12-02 | Personalized skin care compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/025058 WO2022211798A1 (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US18/547,601 A-371-Of-International US12508283B2 (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions |
| US19/405,622 Continuation US20260083779A1 (en) | 2021-03-31 | 2025-12-02 | Personalized skin care compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022211798A1 true WO2022211798A1 (en) | 2022-10-06 |
Family
ID=83459825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2021/025058 Ceased WO2022211798A1 (en) | 2021-03-31 | 2021-03-31 | Personalized skin care compositions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12508283B2 (en) |
| KR (1) | KR102746660B1 (en) |
| CN (1) | CN116916888A (en) |
| AU (1) | AU2021437095A1 (en) |
| BR (1) | BR112023018682A2 (en) |
| GB (1) | GB2619900B (en) |
| MX (1) | MX2023010190A (en) |
| WO (1) | WO2022211798A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130281948A1 (en) * | 2012-04-24 | 2013-10-24 | The Procter & Gamble Company | Substrate Comprising One or More Human Milk Oligosaccharides and Disposable Absorbent Article Comprising the Substrate |
| CN107550808A (en) * | 2017-08-29 | 2018-01-09 | 皖南医学院 | A kind of moisturizing baby's hip pad emulsion of diaper rash of dispelling and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507402B1 (en) | 1997-04-18 | 2009-03-24 | Ganeden Biotech, Inc. | Topical use of probiotic Bacillus spores to prevent or control microbial infections |
| SE9703669D0 (en) | 1997-10-08 | 1997-10-08 | Moelnlycke Ab | Articles and preparation comprising lactic acid bacteria |
| US6756032B1 (en) | 2000-07-12 | 2004-06-29 | The Procter & Gamble Company | Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge |
| MX2012009493A (en) | 2010-02-16 | 2012-12-17 | Playtex Products Llc | Low ph, optimal orp, and odor-reducing fibers, a process for making the fibers, and articles made therefrom. |
| US8945917B2 (en) * | 2011-05-19 | 2015-02-03 | Counci of Scientific & Industrial Research and School of Environmental Studies | Enhanced surface area conico-cylindrical flask (ES-CCF) for biofilm cultivation |
| WO2013187755A1 (en) | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
| TWM462116U (en) * | 2013-04-30 | 2013-09-21 | Tci Co Ltd | Breast milk probiotics microparticle structure with immunomodulatory and anti-allergy effects |
| KR101561002B1 (en) | 2015-02-27 | 2015-10-15 | 주식회사 함소아제약 | Oriental culture medium composition for enhancing growth of lactic acid bacteria and manufacturing method thereof, and lactic acid bacteria cultivation method using the oriental culture medium composition and phamaceutical composition comprising the lactic acid bacteria produced by thereof cultivation method |
| US11304856B2 (en) | 2017-12-12 | 2022-04-19 | Graham Tackle, LLC | Intergluteal shield |
-
2021
- 2021-03-31 AU AU2021437095A patent/AU2021437095A1/en active Pending
- 2021-03-31 US US18/547,601 patent/US12508283B2/en active Active
- 2021-03-31 BR BR112023018682A patent/BR112023018682A2/en unknown
- 2021-03-31 GB GB2315897.5A patent/GB2619900B/en active Active
- 2021-03-31 MX MX2023010190A patent/MX2023010190A/en unknown
- 2021-03-31 KR KR1020237036687A patent/KR102746660B1/en active Active
- 2021-03-31 CN CN202180094818.2A patent/CN116916888A/en active Pending
- 2021-03-31 WO PCT/US2021/025058 patent/WO2022211798A1/en not_active Ceased
-
2025
- 2025-12-02 US US19/405,622 patent/US20260083779A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130281948A1 (en) * | 2012-04-24 | 2013-10-24 | The Procter & Gamble Company | Substrate Comprising One or More Human Milk Oligosaccharides and Disposable Absorbent Article Comprising the Substrate |
| CN107550808A (en) * | 2017-08-29 | 2018-01-09 | 皖南医学院 | A kind of moisturizing baby's hip pad emulsion of diaper rash of dispelling and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| MALGORZATA WITKOWSKA-ZIMNY, EWA KAMIńSKA-EL-HASSAN, EDYTA WRóBEL: "Milk Therapy: Unexpected Uses for Human Breast Milk", NUTRIENTS, vol. 11, no. 5, pages 944, XP055681647, DOI: 10.3390/nu11050944 * |
| SEIFI BAHAR, JALALI SHEIDA, HEIDARI MOHAMMAD: "Assessment effect of breast milk on diaper dermatitis", DERMATOLOGY REPORTS, PAGEPRESS, vol. 9, no. 1, 1 January 2017 (2017-01-01), XP055973696, ISSN: 2036-7392, DOI: 10.4081/dr.2017.7044 * |
| TEUFEL AMBER, HOWARD BRIAN, HU PING, CARR ANDREW N.: "Characterization of the microbiome in the infant diapered area: Insights from healthy and damaged skin", EXPERIMENTAL DERMATOLOGY, BLACKWELL MUNSGAARD, COPENHAGEN; DK, vol. 30, no. 10, 1 October 2021 (2021-10-01), COPENHAGEN; DK , pages 1409 - 1417, XP055973699, ISSN: 0906-6705, DOI: 10.1111/exd.14198 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US12508283B2 (en) | 2025-12-30 |
| BR112023018682A2 (en) | 2023-10-31 |
| US20240226169A1 (en) | 2024-07-11 |
| GB2619900B (en) | 2025-04-09 |
| KR20230153514A (en) | 2023-11-06 |
| GB2619900A (en) | 2023-12-20 |
| GB202315897D0 (en) | 2023-11-29 |
| US20260083779A1 (en) | 2026-03-26 |
| CN116916888A (en) | 2023-10-20 |
| AU2021437095A1 (en) | 2023-11-02 |
| KR102746660B1 (en) | 2024-12-27 |
| MX2023010190A (en) | 2023-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hojsak et al. | Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial | |
| Berggren et al. | Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections | |
| CN107815432B (en) | Inactivated lactobacillus preparation for human and application thereof | |
| CN103249420B (en) | Skin properties improving agent for oral use | |
| Tester et al. | The use of konjac glucomannan hydrolysates to recover healthy microbiota in infected vaginas treated with an antifungal agent | |
| BR112019011015A2 (en) | use of a composition, formulation and its use, prebiotic vaginal lubricant and use of a symbiotic vaginal capsule | |
| Macfarlane et al. | Acquisition, evolution and maintenance of the normal gut microbiota | |
| Honig et al. | Amoxicillin and diaper dermatitis | |
| JP2005516649A (en) | Sanitary tissue impregnated with a composition comprising lactic acid producing bacteria suspended in lipids | |
| CN111701014A (en) | Toothpaste for children and preparation method thereof | |
| CN103251547B (en) | Activated probiotic skin cream and preparation method thereof | |
| US12508283B2 (en) | Personalized skin care compositions | |
| CN113194971A (en) | Method for reducing the transfer of pathogenic microorganisms | |
| EP4210720B1 (en) | Probiotic compositions for the treatment of acne | |
| Lee et al. | Lactobacillus colonization status in infants with urinary tract infection | |
| Tkachenko et al. | Lving” and probiotic” cosmetics: modern view and defenitions | |
| CN107532137A (en) | Lactic acid bacteria and its purposes for treating mastitis | |
| Kang et al. | Effect of Lactobacillus reuteri on the proliferation of Propionibacterium acnes and Staphylococcus epidermidis | |
| Marini et al. | Pre-and probiotics for human skin | |
| Yamashiro et al. | Beneficial microbes for premature infants, and children with malignancy undergoing chemotherapy | |
| Yazdi et al. | The effects of some physicochemical stresses on Escherichia coli O157: H7 as clinical pathogenic bacteria. | |
| Shukla et al. | Role of Probiotics on Gut Microflora | |
| Almjalawi et al. | Antibacterial activity of aqueous extract Cinnamomum zeylanicun against of Klebsiella pneumoniae isolated from Bacteremic patients | |
| EP4119150A1 (en) | Clostridiodes difficile growth inhibitor | |
| Sadanov et al. | First Phase of the Clinical trial of the AS-Probionorm Probiotic Medication for the treatment of Human Intestinal Infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21935384 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18547601 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202180094818.2 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/010190 Country of ref document: MX |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023018682 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 202315897 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20210331 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2315897.5 Country of ref document: GB |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2021437095 Country of ref document: AU Ref document number: AU2021437095 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 20237036687 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020237036687 Country of ref document: KR |
|
| ENP | Entry into the national phase |
Ref document number: 112023018682 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230914 |
|
| ENP | Entry into the national phase |
Ref document number: 2021437095 Country of ref document: AU Date of ref document: 20210331 Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 2315897.5 Country of ref document: GB |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21935384 Country of ref document: EP Kind code of ref document: A1 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2315897.5 Country of ref document: GB |
|
| WWG | Wipo information: grant in national office |
Ref document number: 18547601 Country of ref document: US |